Monte Rosa Therapeutics (NASDAQ:GLUE) CEO Markus Warmuth Sells 5,466 Shares

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) CEO Markus Warmuth sold 5,466 shares of the firm’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $23.49, for a total transaction of $128,396.34. Following the completion of the sale, the chief executive officer directly owned 618,937 shares in the company, valued at $14,538,830.13. This represents a 0.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Monte Rosa Therapeutics Price Performance

GLUE stock traded down $1.03 during mid-day trading on Friday, hitting $24.28. 5,677,440 shares of the stock were exchanged, compared to its average volume of 5,910,646. The business has a fifty day moving average price of $15.78 and a 200 day moving average price of $9.60. Monte Rosa Therapeutics, Inc. has a 12 month low of $3.50 and a 12 month high of $25.77. The stock has a market capitalization of $1.58 billion, a price-to-earnings ratio of 75.88 and a beta of 1.60.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.06. Monte Rosa Therapeutics had a net margin of 11.54% and a return on equity of 8.28%. The company had revenue of $12.77 million during the quarter, compared to analysts’ expectations of $7.37 million. As a group, equities analysts forecast that Monte Rosa Therapeutics, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on GLUE shares. Jefferies Financial Group reiterated a “buy” rating and issued a $31.00 price target on shares of Monte Rosa Therapeutics in a research note on Wednesday. Guggenheim increased their price target on shares of Monte Rosa Therapeutics from $16.00 to $34.00 and gave the company a “buy” rating in a report on Thursday. Cowen reissued a “buy” rating on shares of Monte Rosa Therapeutics in a research report on Wednesday. Zacks Research upgraded shares of Monte Rosa Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday. Finally, Wells Fargo & Company increased their target price on Monte Rosa Therapeutics from $22.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $30.20.

Key Stories Impacting Monte Rosa Therapeutics

Here are the key news stories impacting Monte Rosa Therapeutics this week:

• Positive Sentiment: Interim Phase I data showed MRT‑8102 produces deep NEK7 degradation and drove a large reduction in inflammation markers, which triggered a big intraday rally in the stock. GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug
• Positive Sentiment: Early trial readouts reported ~85% CRP reduction (a key inflammation marker), reinforcing clinical promise for MRT‑8102 and sparking investor enthusiasm. Monte Rosa stock surges after positive data shows 85% CRP reduction
• Positive Sentiment: Analysts reacted to the clinical news with bullish moves — Guggenheim raised its PT to $34 and issued a Buy, and Wells Fargo raised its PT to $30 with an Overweight. These actions support upside from fundamentals if clinical progress continues. Benzinga
• Positive Sentiment: Zacks upgraded GLUE from Hold to Strong Buy amid the data-driven momentum, adding to short‑term buyer interest. Zacks.com upgrade
• Neutral Sentiment: Several market watchers flagged GLUE as a “stock on the move,” highlighting momentum and technical strength that could attract momentum traders. Monte Rosa Therapeutics (GLUE) is on the Move
• Negative Sentiment: Monte Rosa priced an underwritten public offering to raise roughly $300 million: 11,125,000 shares at $24.00 plus 1,375,000 pre‑funded warrants at $23.9999. The timing — immediately after a sharp rally — increases share supply and dilution risk, which likely weighed on the stock. Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

Institutional Trading of Monte Rosa Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. AQR Capital Management LLC increased its position in Monte Rosa Therapeutics by 459.4% in the second quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock worth $5,791,000 after purchasing an additional 1,054,406 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Monte Rosa Therapeutics by 12.0% in the 2nd quarter. Geode Capital Management LLC now owns 1,124,160 shares of the company’s stock valued at $5,071,000 after acquiring an additional 120,098 shares during the last quarter. Marshall Wace LLP grew its position in Monte Rosa Therapeutics by 102.4% in the third quarter. Marshall Wace LLP now owns 902,834 shares of the company’s stock worth $6,690,000 after acquiring an additional 456,754 shares in the last quarter. Vestal Point Capital LP bought a new stake in Monte Rosa Therapeutics during the third quarter worth approximately $5,928,000. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Monte Rosa Therapeutics by 41.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 632,182 shares of the company’s stock worth $4,684,000 after purchasing an additional 184,020 shares during the period. 79.96% of the stock is currently owned by institutional investors.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.